Ayesha Khan

Ayesha Khan

Auto-generated profile, based on publicly available information

Ayesha Khan

Center for Antimicrobial Resistance and Microbial Genomics, University of Texas Health Science Center, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AKAyesha Khan
Ayesha Khan
MDMilya Davlieva
Milya Davlieva
DPDiana Panesso
Diana Panesso
SRSandra Rincon
Sandra Rincon
WMWilliam R. Miller
William R. Miller
CACesar A. Arias
Cesar A. Arias
Bacteria have developed several evolutionary strategies to protect their cell membranes (CMs) from the attack of antibiotics and antimicrobial peptides (AMPs) produced by the innate immune system, including remodeling of phospholipid content and localization. Multidrug-resistant Enterococcus faecalis, an opportunistic human pathogen, evolves resistance to the lipopeptide daptomycin and AMPs by diverting the antibiotic away from critical septal targets using CM anionic phospholipid redistribution. The LiaFSR stress response system regulates this CM remodeling via the LiaR response regulator by a previously unknown mechanism. Here, we characterize a LiaR-regulated protein, LiaX, that senses daptomycin or AMPs and triggers protective CM remodeling. LiaX is surface exposed, and in daptomycin-resistant clinical strains, both LiaX and the N-terminal domain alone are released into the extracellular milieu. The N-terminal domain of LiaX binds daptomycin and AMPs (such as human LL-37) and functions as an extracellular sentinel that activates the cell envelope stress response. The C-terminal domain of LiaX plays a role in inhibiting the LiaFSR system, and when this domain is absent, it leads to activation of anionic phospholipid redistribution. Strains that exhibit LiaX-mediated CM remodeling and AMP resistance show enhanced virulence in the Caenorhabditis elegans model, an effect that is abolished in animals lacking an innate immune pathway crucial for producing AMPs. In conclusion, we report a mechanism of antibiotic and AMP resistance that couples bacterial stress sensing to major changes in CM architecture, ultimately also affecting host–pathogen interactions.

18 October 2021 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
AKAyesha Khan
Ayesha Khan
SESamuel G. Erickson
Samuel G. Erickson
CPCedric Pettaway
Cedric Pettaway
CACesar A. Arias
Cesar A. Arias
WMWilliam R. Miller
William R. Miller
MBMicah M. Bhatti
Micah M. Bhatti
Carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa (CR-PA) producing metallo-β-lactamases (MBLs) cause severe nosocomial infections with no defined treatment. The combination of aztreonam (ATM) with ceftazidime-avibactam (CZA) is a potential therapeutic option, but there is no approved, feasible testing method for use in clinical laboratories to assess the activity of two antimicrobials in combination.

21 September 2022 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
AKAyesha Khan
Ayesha Khan
WMWilliam R. Miller
William R. Miller
DADierdre Axell-House
Dierdre Axell-House
JMJose M. Munita
Jose M. Munita
CACesar A. Arias
Cesar A. Arias
Enterococci are major, recalcitrant nosocomial pathogens with a wide repertoire of intrinsic and acquired resistance determinants and the potential of developing resistance to all clinically available antimicrobials. As such, multidrug-resistant enterococci are considered a serious public health threat.

3 April 2018 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
AKAyesha Khan
Ayesha Khan
WMWilliam R. Miller
William R. Miller
CACesar A. Arias
Cesar A. Arias
The introduction of antibiotics revolutionized medicine in the 20th-century permitting the treatment of once incurable infections. Widespread use of antibiotics, however, has led to the development of resistant organisms, particularly in the healthcare setting. Today, the clinician is often faced with pathogens carrying a cadre of resistance determinants that severely limit therapeutic options. The genetic plasticity of microbes allows them to adapt to stressors via genetic mutations, acquisition or sharing of genetic material and modulation of genetic expression leading to resistance to virtually any antimicrobial used in clinical practice. Areas covered: This is a comprehensive review that outlines major mechanisms of resistance in the most common hospital-associated pathogens including bacteria and fungi. Expert commentary: Understanding the genetic and biochemical mechanisms of such antimicrobial adaptation is crucial to tackling the rapid spread of resistance, can expose unconventional therapeutic targets to combat multidrug resistant pathogens and lead to more accurate prediction of antimicrobial susceptibility using rapid molecular diagnostics. Clinicians making treatment decisions based on the molecular basis of resistance may design therapeutic strategies that include de-escalation of broad spectrum antimicrobial usage, more focused therapies or combination therapies. These strategies are likely to improve patient outcomes and decrease the risk of resistance in hospital settings.

6 June 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
AKAyesha Khan
Ayesha Khan
TTTruc T Tran
Truc T Tran
RRRafael Rios
Rafael Rios
BHBlake Hanson
Blake Hanson
WSWilliam C Shropshire
William C Shropshire
WMWilliam R Miller
William R Miller
Treatment of serious infections due to multidrug-resistant (MDR) Pseudomonas aeruginosa remains a challenge, despite the introduction of novel therapeutics. In this study, we report 2 extensively drug-resistant clinical isolates of sequence type (ST) 309 P aeruginosa resistant to all β-lactams, including the novel combinations ceftolozane/tazobactam, ceftazidime/avibactam, and meropenem/vaborbactam. Isolates were sequenced using both short-read (Illumina) and long-read technology to identify resistance determinants, polymorphisms (compared with P aeruginosa PAO1), and reconstruct a phylogenetic tree. A pair of β-lactamases, Guiana extended spectrum β-lactamase (GES)-19 and GES-26, were cloned and expressed in a laboratory strain of Escherichia coli to examine their relative impact on resistance. Using cell lysates from E coli expressing the GES genes individually and in tandem, we determined relative rates of hydrolysis for nitrocefin and ceftazidime. Two ST309 P aeruginosa clinical isolates were found to harbor the extended spectrum β-lactamases GES-19 and GES-26 clustered in tandem on a chromosomal class 1 integron. The presence of both enzymes in E coli was associated with significantly elevated minimum inhibitory concentrations to aztreonam, cefepime, meropenem, ceftazidime/avibactam, and ceftolozane/tazobactam, compared with those expressed individually. The combination of ceftazidime/avibactam plus aztreonam was active in vitro and used to achieve cure in one patient. Phylogenetic analysis revealed ST309 P aeruginosa are closely related to MDR strains from Mexico also carrying tandem GES. The presence of tandem GES-19 and GES-26 is associated with resistance to all β-lactams, including ceftolozane/tazobactam. Phylogenetic analysis suggests that ST309 P aeruginosa may be an emerging threat in the United States.

18 August 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
AKAyesha Khan
Ayesha Khan
CACesar A. Arias
Cesar A. Arias
AAApril Abbott
April Abbott
JBJennifer Dien Bard
Jennifer Dien Bard
MBMicah M. Bhatti
Micah M. Bhatti
RHRomney Humphries
Romney Humphries
Stenotrophomonas maltophilia causes high-mortality infections in immunocompromised hosts with limited therapeutic options. Many U.S. laboratories rely on commercial automated antimicrobial susceptibility tests (cASTs) and use CLSI breakpoints (BPs) for S. maltophilia .